Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 809 / https://doi.org/10.3332/ecancer.2018.809

Research

Awareness and compliance with pharmacovigilance requirements amongst UK oncology healthcare professionals

Since 2013, once a medicine receives marketing authorisation in the European Union, it is labelled with an inverted black triangle indicating all adverse reactions should be reported. Our aim was to explore understanding of the black triangle and compliance with adverse event (AE) reporting requirements by UK oncology healthcare professionals (HCPs). A questionnaire was electronically distributed to oncology pharmacists (P) via the British Oncology Pharmacy Association, to oncologists (O) through the Association of Cancer Physicians and also to nurses (N) via the UK Oncology Nursing Society. Overall, 125 (42 O, 61 P, 22 N) clinicians participated. The purpose of the black triangle was unknown by 26% (55% O, 5% P, 28% N) and 54% did not alter their AE reporting in the presence of a black triangle. Once the black triangle was removed, only 38% were aware which AEs should be reported, 46% did not report all serious AEs for established medicines, including life-threatening or disabling AEs. Reasons for non-reporting were decision making on what to report (45%); time consumed by reporting (41%); AEs perceived as not serious enough (35%) and follow-up process (23%). Understanding of the pharmacovigilance framework among respondent groups was variable. Across all groups, AEs appear substantially under-reported. Reasons identified in the study include the time consuming nature of AE reporting and a lack of understanding around the black triangle and AE reporting process. There is a need to further support HCP education on AE reporting coupled with a review of the current reporting process to ensure maximal engagement.

Keywords: pharmacovigilance, pharmacists, oncology nursing, surveys and questionnaires, marketing, oncologists

Loading Article Metrics ... Please wait

Related articles

Case Report: Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation

Abstract | Full Article | PDF Published: 20 Sep 2018 / https://doi.org/10.3332/ecancer.2018.872

Conference Report: Highlights from the 2018 WIN Symposium, 25–26 June 2018, Paris: designing the future of precision oncology

Abstract | Full Article | PDF Published: 12 Sep 2018 / https://doi.org/10.3332/ecancer.2018.871

Conference Report: Inspiration, innovation and integration: highlights from the third ICPCN conference on children’s palliative care, 30th May-2nd June 2018, Durban, South Africa

Abstract | Full Article | PDF Published: 11 Sep 2018 / https://doi.org/10.3332/ecancer.2018.870

Special Issue: Pre-, pro- and synbiotics in cancer prevention and treatment—a review of basic and clinical research

Abstract | Full Article | PDF Published: 05 Sep 2018 / https://doi.org/10.3332/ecancer.2018.869

Special Issue: Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment

Abstract | Full Article | PDF Published: 05 Sep 2018 / https://doi.org/10.3332/ecancer.2018.868



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation